Cash/Burn From SEC Filing For Period: 

ARCT

Arcturus Therapeutics

Arcturus Therapeutics is developing a portfolio of mRNA therapeutics for treatment of diseases with unmet medical needs. Our hope and vision are to build transformative, life-changing medicines for patients and their families.

Cash

$71.4M

Burn Rate

$26M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

COVID-19 Vaccine

COVID-19

Phase 1/2 Data

Q4 2020

ARCT-810

OTC (Ornithine Transcarbamylase) Deficiency

Phase 1 Data Readout

Q4 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon